Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October ...

Gene therapy appears to be a promising approach for a subset of genetic deafness, although challenges remain with development ...

Fintel reports that on July 31, 2025, Morgan Stanley upgraded their outlook for Ionis Pharmaceuticals (NasdaqGS:IONS) from ...

A team led by Prof. CHEN Lingling from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences revealed a spatiotemporal separation in the processing of distinct rRNA ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

A new article in the peer-reviewed journal Nucleic Acid Therapeutics describes the characterization of antibodies targeting ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.

Adrian R. Krainer has been awarded the 2025 Heinrich Wieland Prize for his pioneering RNA research that led to the ...